Comparative Pharmacology
Head-to-head clinical analysis: METASTRON versus XENOVIEW.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METASTRON versus XENOVIEW.
METASTRON vs XENOVIEW
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Strontium-89 chloride is a bone-seeking radiopharmaceutical that emits beta radiation. After intravenous administration, it is taken up preferentially by osteoblastic bone metastases, where its beta decay causes DNA damage and cell death in tumor cells.
Xenoview is a paramagnetic contrast agent for MRI that enhances T1 relaxation by shortening the longitudinal relaxation time of water protons in tissues where it accumulates, thereby increasing signal intensity on T1-weighted images.
Metastron (strontium-89 chloride) is administered intravenously at a dose of 148 MBq (4 mCi) as a single injection.
Not applicable (diagnostic agent, not therapeutic); refer to imaging protocol.
None Documented
None Documented
Terminal elimination half-life is approximately 50.5 days (range 20-87 days). Clinical context: due to prolonged retention in bone metastases, radiobiological half-life exceeds physical half-life; therapeutic effect persists for weeks despite declining plasma levels.
Terminal elimination half-life is 3-5 hours in patients with normal renal function; may be prolonged in renal impairment.
Renal excretion of strontium-89; approximately 70% excreted in urine within 48 hours, with the remainder eliminated over weeks via both renal and fecal routes (12-20% fecal).
Primarily renal excretion (60-70% unchanged drug), with 20-25% biliary/fecal elimination.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical